new currency in the usa- Top Related searches

Guotai Junan: The bottom of China stock market has appeared, and the conditions for a "transformation bull" are taking shape. Guotai Junan Securities recently released the prospect of China's equity investment strategy in 2025, and the bottom of China stock market has appeared, and the conditions for a "transformation bull" are taking shape. After a long period of continuous adjustment, pessimistic expectation and clear microstructure, it is a prerequisite for the stock market to have valuation flexibility. The positive change of decision-makers' attitude towards reversing the economic situation and supporting the capital market is an important cornerstone for revising long-term expectations and getting rid of "bear market thinking" and raising the bottom of the stock market. The reform of the capital market will improve shareholders' returns, and resolving debts, promoting reform and stabilizing asset prices are expected to constitute the new "three arrows" of China's economic development, and the transformation bull of China's stock market is taking shape.New World Development sold Artisan Lab in Kowloon, Hong Kong for HK$ 620 million. Sing Tao Daily quoted an unnamed insider as saying that New World Development sold Artisan Lab in San Po Kong, Kowloon for HK$ 620 million. This 22-storey building was completed in 2022, with a floor area of about 120,000 square feet.ADB lowered the growth forecast of developing economies in the Asia-Pacific region to maintain China's economic growth forecast. On December 11th, the Asian Development Bank issued the Asia Development Outlook 2024 (December Edition). According to the report, the development momentum in the Asia-Pacific region is steady, but as US President-elect Trump is about to take office, changes in his trade, finance and immigration policies may inhibit the development of the Asia-Pacific region and aggravate inflation. ADB lowered its growth forecast for developing economies in the Asia-Pacific region from the previous 5.0% to 4.9% in 2024, and from the previous 4.9% to 4.8% in 2025. China's economic growth is expected to remain at 4.8% and 4.5% in 2024 and 2025 respectively, which is the same as before.

Kathy Hochul, the governor of New York, said that a governor's arrest warrant would be issued to the suspect who murdered the CEO of United Health Insurance.New World Development sold Artisan Lab in Kowloon, Hong Kong for HK$ 620 million. Sing Tao Daily quoted an unnamed insider as saying that New World Development sold Artisan Lab in San Po Kong, Kowloon for HK$ 620 million. This 22-storey building was completed in 2022, with a floor area of about 120,000 square feet.Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.

Caoji Group seeks to raise up to HK$ 138 million through Hong Kong IPO. According to the announcement of the Hong Kong Stock Exchange, Caoji Group will issue about 33.3 million shares at a price range of HK$ 3.75 to HK$ 4.15 per share. The company may raise up to HK$ 138 million (US$ 17.8 million) and is expected to start listing on December 19th.Sagitar Juchuang will raise HK$ 277.5 million by placing shares. According to the announcement of the Hong Kong Stock Exchange, the robotics company Sagitar Juchuang agreed to place 10 million new shares at a price of HK$ 27.75 per share. The matching price is about 8% lower than Tuesday's closing price of HK$ 30.15 per share. The proceeds from the placement of shares will be mainly used for research and development, enhancing business development capabilities in overseas markets and exploring potential strategic partnership or alliance opportunities.Japanese manufacturers' confidence index turned negative to the central bank's forecast in December. A short-term survey in Reuters, Japan, found that Japanese manufacturers' business confidence deteriorated further in December due to concerns about US protectionist policies. The survey of 505 large Japanese non-financial enterprises showed that manufacturers' confidence index fell from 5 in November to -1 in December, which was the first time since last February, and the number of pessimists exceeded optimists for the first time in 10 months. The loss of business confidence may cast a shadow over the Bank of Japan's forecast. The Bank of Japan had previously predicted that a steady recovery driven by rising wages and consumption would help inflation reach the 2% target in a sustainable way and justify further interest rate hikes. Many manufacturing industries have reported that business confidence has declined. Among electronic machinery manufacturers, steel and non-ferrous metal manufacturers, pessimists far exceed optimists.